Nymox Pharmaceutical (NYMX +3.4%) says it's completed the patient enrollment process for its...

|About: Nymox Pharmaceutical Corpor... (NYMX)|By:, SA News Editor

Nymox Pharmaceutical (NYMX +3.4%) says it's completed the patient enrollment process for its Phase III trial of NX-1207 for BPH. Top-line results are expected in late 2013, and include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, as well as other clinical and non-clinical research activities.